Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Conditions:   ATM Gene Mutation;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Homologous Recombination Deficiency;   Prostate Carcinoma Metastatic in the Bone;   PSA Level Greater Than or Equal to  Two;   PSA Progression;   Stage IV Prostate Adenocarcinoma AJCC v7 Interventions:   Drug: Carboplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Rucaparib Camsylate Sponsors:   University of Washington;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials